知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

8 records (took 0.012 seconds)

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-A
    1.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-A 有权

    公开(公告)号：US20210032361A1

    公开(公告)日：2021-02-04

    申请号：US16943779

    申请日：2020-07-30

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Meike HUTT ,  Felix UNVERDORBEN ,  Sebastian BUNK ,  Dominik MAURER ,  Martin HOFMANN ,  Gabriele PSZOLLA ,  Sara YOUSEF ,  Claudia WAGNER ,  Frank SCHWOEBEL ,  Heiko SCHUSTER

    IPC: C07K16/30 ,  C07K14/725 ,  A61P35/00

    Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    METHODS FOR GENERATING CELL SPHEROIDS
    4.
    发明公开
    METHODS FOR GENERATING CELL SPHEROIDS 审中-公开

    公开(公告)号：US20230142468A1

    公开(公告)日：2023-05-11

    申请号：US18053165

    申请日：2022-11-07

    Applicant: Immatics US, Inc. ,  Immatics Biotechnologies GmbH

    Inventor： Inbar ALFAGUTER ,  Sara YOUSEF ,  Kathy-Ann SECKER ,  Amir ALPERT ,  Juliane PALMER ,  Maike JAWORSKI

    IPC: C12N5/00

    CPC classification number: C12N5/0062 ,  C12N2533/90 ,  C12N2513/00

    Abstract: The present disclosure relates to improved methods for generating multicellular spheroids. In embodiments, an improved method may comprise (a) providing cells capable of spheroid formation; (b) centrifuging the cells; (c) adding extracellular matrix to the cells of (b) to produce a cell suspension comprising a desired concentration of extracellular matrix; and (d) allowing at least one spheroid to form; wherein (b) is performed before (c). In embodiments, cells may be seeded on a tissue culture apparatus before extracellular matrix is added to the cells. In embodiments, spheroids may be characterized, analyzed, challenged, otherwise tested, or a combination thereof. In embodiments, cells may be seeded in a volume of media that is a fraction of a volume of media that is desired for characterization, analysis, challenging, otherwise testing, or a combination thereof.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME
    5.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME 有权

    公开(公告)号：US20230132241A1

    公开(公告)日：2023-04-27

    申请号：US17793237

    申请日：2020-01-15

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Sebastian BUNK ,  Martin HOFMANN ,  Meike HUTT ,  Dominik MAURER ,  Gabriele PSZOLLA ,  Frank SCHWOEBEL ,  Felix UNVERDORBEN ,  Claudia WAGNER ,  Sara YOUSEF

    IPC: C07K16/30 ,  C12N15/63 ,  A61P35/00

    Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are selective and specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 8 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING CT45
    8.
    发明申请
    ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING CT45 有权

    公开(公告)号：US20230057987A1

    公开(公告)日：2023-02-23

    申请号：US17874711

    申请日：2022-07-27

    Applicant: Immatics Biotechnologies GmbH

    Inventor： Sara YOUSEF ,  Fabian BRUNK ,  Andreas MORITZ ,  Sebastian BUNK ,  Claudia WAGNER ,  Dominik MAURER ,  Felix UNVERDORBEN

    IPC: C07K16/30 ,  C07K14/725 ,  G01N33/574

    Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.

Patent Agency Ranking